GMED: Leadership change

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 3, 2026, Globus Medical, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved an amendment (the “2021 Equity Incentive Plan Amendment”) to the Globus Medical, Inc. 2021 Equity Incentive Plan (the “Plan”) to increase the number of shares authorized thereunder by 1,000,000 (the Plan as amended by the 2021 Equity Incentive Plan Amendment, the “Amended Plan”). The 2021 Equity Incentive Plan Amendment was previously recommended for approval by the Compensation Committee of the Board of Directors of the Company (the “Board”) and approved by the Board, in each case, subject to stockholder approval at the Annual Meeting. The 2021 Equity Incentive Plan Amendment became effective on June 3, 2026 upon stockholder approval and increased the aggregate number of shares authorized for issuance under the Plan to 12,000,000 shares of the Company’s Class A Common Stock. The 2021 Equity Incentive Plan Amendment also increased the aggregate number of shares of Class A Common Stock that may be issued or transferred under the Plan pursuant to incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended, from 11,000,000 to 12,000,000. The material terms of the Amended Plan are described in the section entitled “Proposal 2 – Approval of Amendment to the 2021 Equity Incentive Plan” set forth on pages 15-23 of the Company’s definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 24, 2026 in connection with the Annual Meeting (the “Proxy Statement”), which such description is inc